As a leading expert in the areas of peptide technology and antibodies, Creative Peptides already has API peptides, cosmetic peptides and catalog peptides as its featured products. “With continuous efforts to expand the business range, Creative Peptides never forgets to put customers first, so we decides to launch more featured products specifically targeting at prevalent diseases like diabetes, cancer, heart failure, hypertension,” says the Product Manager at Creative Peptides. “This is our first move, and we expect positive results.”

Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1. On July 3, 2009, liraglutide was first approved for treatment of type 2 diabetes by the European Medicines Agency (EMA), and about half a year later on January 25, 2010, it received approval from the U.S. Food and Drug Administration (FDA). Developed by Novo Nordisk for the treatment of type 2 diabetes, liraglutide was marketed under the brand name Victoza as an injectable drug.

“Compared with other traditional therapies for type 2 diabetes, liraglutide has many advantages,” explains the leading scientist of the diabetes team at Creative Peptides. “For example, it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing ‘overshoot’; meanwhile, it also has the potential for inhibiting apoptosis and stimulating regeneration of beta cells…”

The therapeutic function of liraglutide for the treatment of type 2 diabetes has been tested over the last few years. More recently in 2015, liraglutide was marketed under the brand name Saxenda as a treatment for adults with obesity problems.

About Creative Peptides

With over a dozen of years’ unremitting efforts in the pharmaceutical industry, Creative Peptides has achieved considerably in not only providing a comprehensive collection of research peptides, but also offering related services like custom peptide synthesis, peptide drug conjugations, etc. With the advantage of world-class scientific teams consisting of experts in multiple fields like peptide technology, antibodies as well as synthetic chemistry, Creative Peptides now focus more on satisfying different needs of customers by planning to launch more featured products targeting at different major diseases, in a hope to facilitate the search work of clients.

Media Contact
Company Name: Creative Peptides
Contact Person: Caroline Miller
Email: contact@creative-peptides.com
Phone: 1-631-619-7922
Address:45-16 Ramsey Road
City: Shirley
State: NY
Country: United States
Website: www.creative-peptides.com/